Verrica Pharmaceuticals Inc
NASDAQ:VRCA
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.643
9.56
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Verrica Pharmaceuticals Inc
Verrica Pharmaceuticals Inc
Free Cash Flow
Verrica Pharmaceuticals Inc
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Verrica Pharmaceuticals Inc
NASDAQ:VRCA
|
Free Cash Flow
-$65.9m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Free Cash Flow
$20.7B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
1%
|
CAGR 10-Years
4%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Free Cash Flow
$13.8B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
13%
|
CAGR 10-Years
15%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Free Cash Flow
$4.8B
|
CAGR 3-Years
-45%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-11%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Free Cash Flow
$14.8B
|
CAGR 3-Years
21%
|
CAGR 5-Years
11%
|
CAGR 10-Years
3%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Free Cash Flow
-$2.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Verrica Pharmaceuticals Inc
Glance View
Verrica Pharmaceuticals, Inc. engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. The company is headquartered in West Chester, Pennsylvania and currently employs 38 full-time employees. The company went IPO on 2018-06-15. The firm is focused on developing and commercializing treatments for skin diseases. The firm's lead product candidate, VP-102, is a drug-device combination of its topical solution of cantharidin, a widely recognized, naturally sourced agent to treat topical dermatological conditions, administered through its single-use precision applicator. The company is developing VP-102 for the treatment of molluscum contagiosum (molluscum), a highly contagious and primarily pediatric viral skin disease, external genital warts and common warts. The company also intends to develop its second cantharidin-based product candidate, VP-103, for the treatment of plantar warts, which are warts located on the bottom of the foot. The company also intends to develop its third product candidate, LTX-315, for the treatment of dermatological oncology indications, including non-metastatic melanoma and non-metastatic Merkel cell carcinoma.
See Also
What is Verrica Pharmaceuticals Inc's Free Cash Flow?
Free Cash Flow
-65.9m
USD
Based on the financial report for Sep 30, 2024, Verrica Pharmaceuticals Inc's Free Cash Flow amounts to -65.9m USD.
What is Verrica Pharmaceuticals Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
-20%
Over the last year, the Free Cash Flow growth was -126%. The average annual Free Cash Flow growth rates for Verrica Pharmaceuticals Inc have been -36% over the past three years , -20% over the past five years .
You don't have any saved screeners yet
